

**BREAKING RESULTS OF EXINI bone™ STUDY PUBLISHED IN EUROPEAN UROLOGY**

**EXINI bone™ provides valuable clinical information at treatment of men with prostate cancer. This is shown in a study made at Memorial Sloan-Kettering Cancer Center in New York, one of the leading hospitals within cancer treatment in USA. The study shows that EXINI bone provides a more objective as well as a faster calculation of the BSI (Bone Scan Index) and can replace the time consuming manual method.**

Prostate cancer is the most frequent form of cancer in the Western world, closely followed by breast cancer. The disease is today often detected early when using the PSA blood test as a screening method. The PSA value is then used to follow the development of the disease. Scientists are looking for additional biomarkers that can improve the ability to determine when a treatment should be initiated and then follow the effect of a treatment. This is where EXINI's automatic BSI calculation can be of great importance.

Published study in European Urology, the leading medical journal in its field, which is read by more than 20,000 urologists around the world:

*Ulmert D, et al. "A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index." Eur Urol (2012), doi:10.1016/j.eururo.2012.01.037 Conclusion:"Automated BSI scoring, with its 100% reproducibility, reduces turnaround time, eliminates operator-dependent subjectivity, and provides important clinical information comparable to that of manual BSI scoring."*

Prostate cancer spreads to the skeleton and bone scan examination is used to observe this. With EXINI's automatic BSI scoring the doctors get a measure of how much the cancer has spread. This has proven to be very important for prognosis. Many patients live for years with prostate cancer without any symptoms, while others have a much more aggressive course of illness. The study shows that a low BSI score was associated with a good prognosis.

The science team at Memorial Sloan-Kettering Cancer Center in New York presented the basic idea to calculate the BSI and has also published reports that have shown that it is a valuable diagnostic tool. The method has not yet received any major distribution due to the lack of clinical tools for calculating the BSI. The newly published article confirms that EXINI offers a totally unique product in that respect.

Lars Edenbrandt, Scientific Director & Founder of EXINI Diagnostics AB, comments:

*"The success of BSI and the attention it has given through the collaboration with Memorial Sloan-Kettering Cancer Center and the publication in European Urology is very inspiring. To EXINI it is equally important to get a receipt that this advanced product that we market can have a significant impact while treating some of the major cancers."*

**For more information, please contact:**

Magnus Aurell, CEO

Phone: +46 46-286 54 25

E-mail: [magnus.aurell@exini.com](mailto:magnus.aurell@exini.com)

**About EXINI Diagnostics AB (publ)**

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 400 shareholders. Principal owner is Bo Håkansson. Thenberg Fondkommission AB acts as Certified Adviser.